Literature DB >> 8045955

Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.

T Hoelting1, A E Siperstein, O H Clark, Q Y Duh.   

Abstract

The prognosis of patients with follicular (FTC) and papillary (PTC) thyroid cancer depends on age and the size and extent of the tumor. Differentiated thyroid cancers bind more epidermal growth factor (EGF) than normal thyroid tissue, but the role of EGF in the proliferation and invasion of thyroid cancer is unknown. We investigated the effects of EGF on growth, migration, and invasion in a follicular thyroid cancer that metastasized to cervical lymph nodes and the lung (FTC 133, primary; FTC 236, lymph node; and FTC 238, lung metastasis) and in a papillary thyroid cancer (PTC-UC3). As measured by the formazan method (dimethylthiazol-diphenyltetrazolium bromide), EGF caused a dose- and time-dependent increase in the growth of FTC 133 and PTC-UC3 by 25%, but its stimulatory effect on growth of the metastatic FTC subclones was smaller (FTC 236, 14%; FTC 238, 8%; P < 0.001). EGF also enhanced the ability of all cell lines to migrate (through 8-microns pore membranes without Matrigel) or invade (membranes with Matrigel). Migration of FTC 133 was enhanced from 86% migrated tumor cells to 95% after 72 h (P < 0.02). Again, stimulation by EGF was lower in FTC 236 and FTC 238. EGF increased migration in PTC-UC3 from 49% to 58%. EGF stimulated invasion of FTC 133 from 17.5% to 24.9%. In the absence of EGF, FTC 238 was the most invasive tumor, but, again, the EGF stimulatory effect was less pronounced than in the primary tumor. EGF stimulated the invasion of PTC-UC3 from 10.9% to 14.3% (P < 0.03). EGF also stimulated the growth of thyroid cancer xenografts in nude mice. Although all FTC cell lines were 100% tumorigenic in nude mice, PTC-UC3 was less tumorigenic. However, after sc inoculation of EGF-pretreated tumor cells, 7 of 10 animals developed tumors (mean size, 2.3 cm3) compared to 2 of 10 animals (mean size, 1.4 cm3) in the control group (P < 0.02). In summary, EGF stimulates the growth and invasion of differentiated thyroid cancer cells in culture and in nude mice. Escape from growth factor control, such as in FTC 236 and FTC 238, may be an important step in the development of metastatic thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045955     DOI: 10.1210/jcem.79.2.8045955

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Do Statins Affect Thyroid Volume and Nodule Size in Patients with Hyperlipidemia in a Region with Mild-to-Moderate Iodine Deficiency? A Prospective Study.

Authors:  Canan Demir; Cuneyd Anil; Yusuf Bozkus; Umut Mousa; Altug Kut; Asli Nar; Neslihan B Tutuncu
Journal:  Med Princ Pract       Date:  2018-01-23       Impact factor: 1.927

2.  Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.

Authors:  Manoj Garg; Deepika Kanojia; Ryoko Okamoto; Saket Jain; Vikas Madan; Wenwen Chien; Abhishek Sampath; Ling-Wen Ding; Meng Xuan; Jonathan W Said; Ngan B Doan; Li-Zhen Liu; Henry Yang; Sigal Gery; Glenn D Braunstein; H Phillip Koeffler
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

Review 3.  Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.

Authors:  Yvette Carter; Renata Jaskula-Sztul; Herbert Chen; Haggi Mazeh
Journal:  Neuroendocrinology       Date:  2012-02-14       Impact factor: 4.914

4.  EGF stimulates lamellipod extension in metastatic mammary adenocarcinoma cells by an actin-dependent mechanism.

Authors:  J E Segall; S Tyerech; L Boselli; S Masseling; J Helft; A Chan; J Jones; J Condeelis
Journal:  Clin Exp Metastasis       Date:  1996-01       Impact factor: 5.150

5.  Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.

Authors:  Sonja Šelemetjev; Aleksandar Bartolome; Tijana Išić Denčić; Ilona Đorić; Ivan Paunović; Svetislav Tatić; Dubravka Cvejić
Journal:  Int J Exp Pathol       Date:  2018-04-17       Impact factor: 1.925

6.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

7.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

8.  The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells.

Authors:  Aleksandra Glogowska; Janette Pyka; Astrid Kehlen; Marek Los; Paul Perumal; Ekkehard Weber; Sheue-yann Cheng; Cuong Hoang-Vu; Thomas Klonisch
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

9.  Epidermal growth factor receptor and claudin-2 participate in A549 permeability and remodeling: implications for non-small cell lung cancer tumor colonization.

Authors:  Yakov Peter; Alejandro Comellas; Elena Levantini; Edward P Ingenito; Steven D Shapiro
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

10.  Medullary thyroid carcinoma: targeted therapies and future directions.

Authors:  Scott N Pinchot; Muthusamy Kunnimalaiyaan; Rebecca S Sippel; Herbert Chen
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.